Patient-Focused Science Targets Rare Genetic Disorders: An Expert Analysis
In the world of neuroscience, few experiences can match the profound impact of a single moment that sparks a lifelong passion. For Shannon Knight, that moment came during a high school medical day, where she held the brain of a patient who had passed away from Alzheimer's. This encounter ignited her interest in neuroscience, and she has since dedicated her career to understanding and treating rare genetic disorders.
Knight's current research focuses on developing a novel gene therapy for SYNGAP1 haploinsufficiency, a rare genetic disorder caused by a mutation in the SYNGAP1 gene. This disorder leads to seizures in children as young as 4 months old, as well as intellectual disabilities, feeding and sleeping challenges, and movement difficulties. While current treatments address symptoms, they often become ineffective over time.
Knight's approach is to target the root cause of the disorder using CRISPR, a biotechnology tool for gene editing. By focusing on the gene itself, her research aims to provide a more permanent solution for patients. This is a testament to her belief in the power of empathy in scientific research, as she strives to benefit those affected by these disorders.
Her journey into gene therapy began at Bowdoin College, where she studied neuroscience and worked with Professor Hadley Horch. Initially planning to be pre-med, Knight's honors thesis on neuron regeneration in crickets sparked her interest in molecular neuroscience and genetics. This led her to the Perrimon Lab at Harvard University, where she learned about CRISPR and applied it in a fruit fly model.
Knight's passion for neuroscience and genetics led her to MIT's McGovern Institute for Brain Research, where she works with Professor Guoping Feng. Together, they are developing gene therapy for Phelan-McDermid Syndrome, a rare genetic disorder caused by a deletion or mutation on the 22nd chromosome. The research is now in clinical trials, and Knight is in the early stages of testing gene therapy for SYNGAP1 disorder.
The testing of the gene therapy on mice with a version of SYNGAP1 disorder has shown promising results, alleviating seizures and behavioral phenotypes. This work is being accelerated by the Rare Brain Disorders Nexus, an MIT initiative launched in 2025. Knight's dedication to rare genetic disorders is driven by her desire to give hope to those who feel invisible in the healthcare system.
Beyond her research, Knight has developed a love for teaching. She has been a teaching assistant for Experimental Molecular Neurobiology, leading the lab portion of the course. Her close work with small classes of students has introduced them to the fundamentals of neuroscience lab research. Knight's commitment to teaching was recognized with the Goodwin Medal in 2025, and she continues to inspire and educate the next generation of scientists.
In conclusion, Shannon Knight's patient-focused approach to science is a beacon of hope for those affected by rare genetic disorders. Her dedication to empathy, teaching, and groundbreaking research makes her an exceptional scientist and a valuable asset to the field of neuroscience. As her work continues to advance, it will undoubtedly have a profound impact on the lives of many.
